Corona Remedies IPO Day 1
The highly anticipated Corona Remedies IPO Day 1 opened for public subscription on December 8, 2025. Investors across India are closely watching this offering, given the company’s strong presence in the pharmaceutical sector and its track record of robust growth.
Why is this IPO trending? Corona Remedies, a Gujarat-based pharma manufacturer, is offering 0.62 crore shares entirely via an offer-for-sale (OFS), allowing existing shareholders like Sepia Investments, Anchor Partners, and Sage Investment Trust to partially divest. While the company won’t receive fresh capital, the IPO is a pivotal opportunity for retail and institutional investors to gain exposure to a growing pharmaceutical player.
Corona Remedies IPO Day 1: Price Band and Subscription Details
The Corona Remedies IPO Day 1 price band has been fixed between ₹1,008 and ₹1,062 per equity share. Retail investors can apply for a minimum of one lot of 14 shares, which translates to an investment of ₹14,868 at the upper band. Subsequent bids can be made in multiples of 14 shares.
The total issue size is ₹655.37 crore, structured as follows:
- Retail Investors: 35%
- Qualified Institutional Buyers (QIBs): 50%
- Non-Institutional Investors (NIIs): 15%
Before the IPO, Corona Remedies raised ₹194.85 crore from 15 institutional investors via the anchor book, including SBI Mutual Fund, ICICI Prudential MF, Kotak Mahindra AMC, and Axis MF.
Key Dates for Corona Remedies IPO
| Event | Date |
|---|---|
| IPO Open | December 8, 2025 |
| IPO Close | December 10, 2025 |
| Basis of Allotment | December 11, 2025 |
| Refunds & Share Credit | December 12, 2025 |
| Listing on BSE & NSE | December 15, 2025 |
These dates are crucial for investors planning to participate in Corona Remedies IPO Day 1 or the subsequent subscription days.
Should You Subscribe to Corona Remedies IPO?
Anand Rathi has rated the IPO as Subscribe for long term, citing the company’s strategic positioning and robust growth trajectory. Key highlights include:
- Above-industry growth: Corona Remedies continues to outperform the Indian Pharmaceutical Market, growing at a 16.77% CAGR, the second fastest among the top 30 pharma companies.
- Strong brand portfolio: Leadership across multiple therapeutic segments, including women’s healthcare, cardio-diabetes, pain management, and urology.
- Revenue and Profit Growth: For FY25, the company reported a net profit of ₹149.43 crore on total revenues of ₹1,196.41 crore. The Q2 FY26 net profit stood at ₹46.19 crore with core revenue of ₹346.54 crore.
- Strategic Execution: Continuous expansion in chronic and sub-chronic therapies, combined with steady scale-up of recent product launches.
Despite the company’s fully priced valuation with a P/E of 35.3 times (based on annualised FY26 earnings) and post-issue market capitalization of ₹64,952 million, the long-term growth potential, robust pipeline, and market share gains make it attractive for investors seeking long-term exposure.
About Corona Remedies
Corona Remedies is a pharmaceutical manufacturer headquartered in Gujarat with two operational manufacturing units—one in Gujarat and another in Himachal Pradesh. Its portfolio spans several therapeutic segments:
- Women’s Healthcare
- Cardio-Diabetes
- Pain Management
- Urology
- Other Specialty Therapies
The company focuses on sustainable growth through strategic expansion, new product launches, and strong brand positioning across key therapy areas.
Final Thoughts on Corona Remedies IPO Day 1
The Corona Remedies IPO Day 1 represents a significant opportunity for investors looking to tap into India’s growing pharmaceutical sector. With strong fundamentals, an experienced management team, and a diversified product portfolio, the company is well-positioned for long-term growth.
Investors should carefully consider their risk appetite, the IPO’s valuation, and long-term prospects before subscribing. The subscription window closes on December 10, and successful applicants will likely receive shares on December 12, with listings expected on BSE and NSE by December 15.
